JP2005535664A - インターフェロン−α治療に関連した精神病を処置するための方法 - Google Patents

インターフェロン−α治療に関連した精神病を処置するための方法 Download PDF

Info

Publication number
JP2005535664A
JP2005535664A JP2004519990A JP2004519990A JP2005535664A JP 2005535664 A JP2005535664 A JP 2005535664A JP 2004519990 A JP2004519990 A JP 2004519990A JP 2004519990 A JP2004519990 A JP 2004519990A JP 2005535664 A JP2005535664 A JP 2005535664A
Authority
JP
Japan
Prior art keywords
interferon
glucocorticoid receptor
patient
receptor antagonist
glucocorticoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004519990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535664A5 (enExample
Inventor
ジョセフ ケー． ベラノフ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2005535664A publication Critical patent/JP2005535664A/ja
Publication of JP2005535664A5 publication Critical patent/JP2005535664A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004519990A 2002-07-02 2003-07-02 インターフェロン−α治療に関連した精神病を処置するための方法 Pending JP2005535664A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39366002P 2002-07-02 2002-07-02
PCT/US2003/021245 WO2004004653A2 (en) 2002-07-02 2003-07-02 Methods for treating psychosis associated with interferon-alpha therapy

Publications (2)

Publication Number Publication Date
JP2005535664A true JP2005535664A (ja) 2005-11-24
JP2005535664A5 JP2005535664A5 (enExample) 2006-10-26

Family

ID=30115622

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004519990A Pending JP2005535664A (ja) 2002-07-02 2003-07-02 インターフェロン−α治療に関連した精神病を処置するための方法

Country Status (6)

Country Link
US (1) US8476254B2 (enExample)
EP (1) EP1534299A4 (enExample)
JP (1) JP2005535664A (enExample)
CN (1) CN1665515A (enExample)
CA (1) CA2491296C (enExample)
WO (1) WO2004004653A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
CA2676670C (en) 2007-02-02 2012-03-13 Pfizer Products Inc. Tricyclic compounds, compositions, and methods
EP1987814A1 (en) * 2007-04-30 2008-11-05 Exelgyn Mifepristone pharmaceutical compositions and their methods of preparation
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
WO2012106514A2 (en) * 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
US9598459B2 (en) * 2015-08-03 2017-03-21 Pop Test Oncology Llc Pharmaceutical compositions and methods
KR102342620B1 (ko) 2017-03-31 2021-12-22 코어셉트 쎄라퓨틱스 인코포레이티드 자궁경부암을 치료하기 위한 글루코코르티코이드 수용체 조정제
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
SG11202105770YA (en) 2018-12-19 2021-07-29 Corcept Therapeutics Inc Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
EP3927345A4 (en) 2019-02-22 2022-12-21 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN119997939A (zh) 2022-10-06 2025-05-13 科赛普特治疗公司 糖皮质激素受体调节剂的制剂
CN120202004A (zh) 2022-10-28 2025-06-24 科赛普特治疗学股份有限公司 使用达祖可兰治疗肌萎缩侧索硬化症

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
AU5374798A (en) * 1996-12-05 1998-06-29 Bio-Technology General Corporation Uses of oxandrolone
CN1528315A (zh) * 1997-10-06 2004-09-15 ������˹̹�������ѧ�й�ίԱ�� 治疗糖皮质素功能失调相关性精神病的方法
CN1130200C (zh) * 1998-05-15 2003-12-10 利兰·斯坦福青年大学托管委员会 用于治疗痴呆的糖皮质激素受体拮抗剂
AU6508899A (en) * 1998-10-13 2000-05-01 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
CA2352205A1 (en) * 1998-11-24 2000-06-08 Hollis-Eden Pharmaceuticals, Inc. Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other togaviruses
US6340696B1 (en) 1999-03-31 2002-01-22 The Procter & Gamble Company Viral treatment
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
AU2001255495A1 (en) 2000-04-20 2001-11-07 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection

Also Published As

Publication number Publication date
CA2491296A1 (en) 2004-01-15
US20060063748A1 (en) 2006-03-23
US8476254B2 (en) 2013-07-02
CN1665515A (zh) 2005-09-07
WO2004004653A2 (en) 2004-01-15
AU2003269898A1 (en) 2004-01-23
WO2004004653A3 (en) 2004-08-26
EP1534299A2 (en) 2005-06-01
CA2491296C (en) 2012-05-22
EP1534299A4 (en) 2007-04-11

Similar Documents

Publication Publication Date Title
US6362173B1 (en) Methods for treating psychosis associated with cocaine addiction with glucocorticoid receptor antagonists
JP2009102413A (ja) 抗神経病薬誘導性体重増加を予防するための方法
US20210128584A1 (en) Use of glucocorticoid receptor antagonists for the treatment of amyotrophic lateral sclerosis
JP2005535664A (ja) インターフェロン−α治療に関連した精神病を処置するための方法
JP2004525135A (ja) 糖質コルチコイドレセプター特異的アンタゴニストを使用するストレス障害を処置するための方法
JP2006507311A (ja) 胃食道逆流性疾患を処置するための方法
AU2004208842B2 (en) Antiglucocorticoids for the treatment of postpartum psychosis
JP2005501882A (ja) ダウン症候群を有する成人において認知低下を阻害する方法
AU2004259011B2 (en) Antiglucocorticoids for the treatment of catatonia
AU2003269898B2 (en) Methods for treating psychosis associated with interferon-alpha therapy

Legal Events

Date Code Title Description
A625 Written request for application examination (by other person)

Free format text: JAPANESE INTERMEDIATE CODE: A625

Effective date: 20060630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060810

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20060810

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20060810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100105